Th(is)²modeling - Bibliography - modeling, disease, model, disease modeling, early model, global model, core model, budget impact, cost-Effectiveness, cost-utility, health Economics, real world evidence, RWE, cardiology, cardiovascular, renal, respiratory, Metabolic, Diabetes, Obesity, Disease, Delphi, Advisory board, Key opinion leader, Target literature search, Literature review, Piggyback, Country adaptation, Training, HEOR,Burden Of illness, Cost of illness, Unit costs, Quality of life, Utility, ICER, institute for clinical and economic review, economic, clinical, ICUR, conference, undergraduate, research, NMB, Value for money, Affordable, Affordability, Indirect comparison, NMA, C++ ,R, TreeAge, Decision trees, Markov, Markov model, Patient level data, patient, EMR, electronic, medical, records,patient chart review, chart, review, Retrospective, study, Retrospective study, Observational study, Microsimulation, First order, Second order, Monte Carlo, Scenario, Sensitivity analysis, analysis, one way, deterministic, probabilistic

full articles

2024

Ting Zhao, Michelle Tew, Talitha Feenstra, Pieter van Baal, Michael Willis, William J. Valentine, Philip M. Clarke, Barnaby Hunt, James Altunkaya, An Tran-Duy, Richard F. Pollock, Samuel J. P. Malkin, Andreas Nilsson, Phil McEwan, Volker Foos, Jose Leal, Elbert S. Huang, Neda Laiteerapong, Mark Lamotte, Harry Smolen, Jianchao Quan, Luís Martins, Mafalda Ramos & Andrew J. Palmer. The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-024-00914-z.
Mafalda Ramos, Laetitia Gerlier, Anastasia Uster, Louise Muttram, Dominik Steubl, Andrew H Frankel, Mark Lamotte. Development and Validation of a Chronic Kidney Disease Progression Model Using Patient-Level Simulations. Renal Failure (IRNF) https://doi.org/10.1080/0886022X.2024.2406402
Altunkaya J, Li X, Adler A, Feenstra T, Fridhammar A, Keng MJ, Lamotte M, McEwan P, Nilsson A, Palmer AJ, Quan J, Smolen H, Tran-Duy A, Valentine W, Willis M, Leal J, Clarke P, Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge, Value in Health (2024), doi: https://doi.org/10.1016/j.jval.2024.06.010.
Pavol Kral, Thomas Holst-Hansen, Anamaria V. Olivieri, Cristina Ivanescu, Mark Lamotte, Sara Larsen. The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight-Loss Intervention Studies. Advances in Therapy 2024. ADTH-D-24-00217R2. DOI: 10.1007/s12325-024-02932-8
Ichiro Tatsuno, Laetitia Gerlier, Anamaria-Vera Olivieri, James Baker-Knight, Mark Lamotte. Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation. Accepted by BMJ Public Health on May 22 2024.
Mafalda Ramos , Laetitia Gerlier, Anastasia Uster, Louise Muttram, Andrew H. Frankel, Mark Lamotte. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom. Journal of Medical Economics (IJME) 2024. https://doi.org/10.1080/13696998.2024.2357041
Silva Miguel L, Soares M, Olivieri A, Sampaio F, Lamotte M, Shukla S, Conde V, Freitas P, Costa J, Borges M. Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal. Diabetol Metab Syndr. 2024 Apr 30;16(1):97. doi: 10.1186/s13098-024-01338-4.
Michael F. Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom. The Cost-Effectiveness of a Bimekizumab Versus IL-17A inhibitors Treatment-Pathway in Patients with Active Axial Spondyloarthritis in Scotland Journal of Medical Economics 2024: https://doi.org/10.1080/13696998.2024.2342209
Mohammed AlHarbi, Abdullah Othman, Ahmed Ali Nahari, Ahmed Hamdan Al-Jedai, Daniel Cuadras, Faisal Almalky, Fayez AlAzmi, Hajer Yousef Almudaiheem, Hamad AlShubrumi, Hameed AlSwat, Homaid AlSahafi, Kamelia Sindi, Khadija Basaikh, Majed AlQahtani, Mark Lamotte , Moataz Yahia, Mohamed El-Khedr Hassan, Mohammed AlMutlaq, Mohammed AlRoaly, Somaya AlZelaye, Zein AlGhamdi. Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study. Adv Ther. 2024 Jan 19. doi: 10.1007/s12325-023-02772-y.

2023

chan k, hansen k, muratov s, khoudigian s, lamotte m. smart connected insulin dose monitoring technologies versus soc: a canadian cost-effectiveness analysis. accepted for publication in journal of comparative effectiveness research on december 18 (2023) e230124 10.57264/cer-2023-0124.
olivieri av, muratov s, larsen s, luckevich m, chan k, lamotte m, lau dcw. cost-effectiveness of weight-management pharmacotherapies in canada: a societal perspective. accepted for publication in international journal of obesity on december 15 2023.
joseph e. biskupiak, mafalda ramos, carol j. levy, greg forlenza, colin hopley, jennifer boyd, dan swift, mark lamotte, diana i brixner. cost-effectiveness of the tubeless automated insulin delivery system versus standard of care in the management of type 1 diabetes in the united states. j manag care spec pharm. 2023;29(6):1-11.

2022

richard j. auchus, carine courtillot, adrian dobs, diala el-maouche, henrik falhammar, andre lacroix, mallory farrar, conor o'donoghue, milena anatchkova, katelyn cutts, natalie taylor, chuck yonan, mark lamotte, philippe touraine. treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: a modified delphi consensus study. frontiers in endocrinology, 13:1005963 doi 10.3389/fendo.2022.1005963
ehlers lh, lamotte m, ramos m, sandgaard s, holmgaard p, kristensen mm, ejskjaer n. the cost- effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on metformin alone in denmark. diabetes therapy.
v. manteigas, l. martins, j. cruz, m. fonseca, a.p. jesus. erya-bulk and erya-profiling: an application for quantitative pige analysis. computer physics communications, 2022; 275: 108307.

2021

michelle tew, michael willis, christian asseburg, andreas nilsson, an tran-duy, mark lamotte, mafalda ramos, lei si, hui shao, lizheng shi, ping zhang, phil mcewan, wen ye, william h. herman, shihchen kuo, chunting yang, deanna isaman, wendelin schramm, fabian sailer, alan brennan, laura heathcote, daniel pollard, chloe thomas, harry j. smolen, james gahn, rishi patel, josé leal, alastair gray, talitha feenstra, andrew j. palmer, philip clarke. exploring structural uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic simulation models: findings from the ninth mount hood diabetes quality-of-life challenge. medical decision making 2021. 1-13
jendle j, eeg-olofsson k, svensson am, franzen s, lamotte m, levrat-guillen f. cost- effectiveness of the freestyle libre ® system versus blood glucose self-monitoring in individuals with type 2 diabetes on insulin treatment in sweden. diabetes therapy 2021 .
jendle j, eeg-olofsson k, svensson am, franzen s, lamotte m, levrat-guillen f. cost- effectiveness of the freestyle libre system versus self-monitoring of blood glucose in people with type 2 diabetes on insulin treatment not reaching glycemic goals in sweden. accepted for poster presentation at american diabetes association's (ada's) 81st scientific sessions. poster presentation number 135-lb.
ehlers lh, lamotte m, ramos m, sandgaard s, holmgaard p, frary ec, ejskjaer n. the cost- effectiveness of oral semaglutide versus empagliflozin in type 2 diabetes in denmark. journal of comparative effectiveness research 2021. doi: 10.2217/cer-2021-0169.
mccrimmon rj, lamotte m, ramos m, alsaleh ajo, souhami e, lew e. cost-effectiveness of iglarlixi versus ideglira in type 2 diabetes mellitus inadequately controlled by glp-1 receptor agonists and oral antihyperglycemic therapy. diabetes therapy 2021 .
ramos m, men p, wang x, ustyugova a, lamotte m. cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in china. cost ef resour alloc (2021) 19:46 .
owusu-ofori s, sekongo ym, rajab ja, asamoah-akuoko l, magutu v, bah a, lamotte m, dierick k. health economic value of blood in kenya, ghana and ivory coast: the case of maternal bleeding. africa sanguine 2021; vol 23: number 1.
salem a, hu h, ramos m, zhong h, lamotte m. potential clinical and economic impact of optimised maintenance therapy on discharged copd patients after hospitalisation for an exacerbation in china. bmj open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664.
cai r, gerlier l, eichner m, schwehm m, majaram s, mould-quevedo j, lamotte m. cost- effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in germany. journal of medical economics 2021.
ehlers lh, lamotte m, monteiro s, sandgaard s, holmgaard p, frary ec, ejskjaer n. the cost- effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease. diabetes therapy
lopes s, meincke hh, lamotte m, olivieri ava, lean m. a novel decision model to predict the impact of weight management interventions: the core obesity model. obesity science & practice 2021.
nuno marques, laetitia gerlier, mafalda ramos, helder pereira, sérgia rocha, ana catarina fonseca, ana andré, ricardo melo, eduard sidelnikov. patient and caregiver productivity loss and indirect costs associated with cardiovascular events in portugal. perda de produtividade e custos indiretos de doentes e cuidadores associados a eventos cardiovasculares em portugal. revista portuguesa de cardiologia. 2021.40 (2): 109-115
martindale c.s, ramos m, roberti g, roberts p, taylor k, sacks g. multicenter prospective evaluation of parenteral nutrition preparation time and resource utilization: 3-chamber bags compared with hospital pharmacy-compounded bags. jpen j parenter enteral nutr. 2021 sep;45(7):1552-1558.
l. martins, p. amaro, s. pessanha, m. guerra, j. machado, m. l. carvalho. j. p. santos and p. indelicato. overview and calculation of x-ray k-shell transition yields for comprehensive data libraries. x-ray spectrometry. 2020; 49:398-423.

2020

salem a, men p, ramos m, zhang yj, ustyugova a, lamotte m. cost-effectiveness analysis of empagliflozin compared to glimepiride in patients with type 2 diabetes in china. journal of comparative effectiveness research 2021.
ramos m, cummings hm, ustyugova a, raza is, de silva su, lamotte m. long-term cost- effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the uk. diabetes therapy 2020; 11(9), 2041-2055; .
lopes s, johansen p, lamotte m, mcewan p, olivieri av, foos v. external validation of the core obesity model to assess the cost effectiveness of weight management interventions. pharmacoeconomics 2020.
lopes s, johansen p, lamotte m, mcewan p, olivieri av, foos v.authors' reply to comment on "external validation of the core obesity model to assess the cost-effectiveness of weight management interventions". pharmacoeconomics. 2021 jan;39(1):137-138. doi: 10.1007/s40273- 020-00982-8. epub 2020 nov 30.
ramos m, ustyugova a, hau n, lamotte m. the cost-effectiveness of empagliflozin compared to liraglutide based on cardiovascular outcome trials in type 2 diabetes. journal of comparative effectiveness research 2020. /li>
si l, willis ms, asseburg c, tew m, clarke pm, lamotte m, ramos m, hui s, shi l, zhang p, mcewan p, ye w, herman wh, isaman dj, kuo s, schramm w, sailer f, brennan a, pollard d, smolen hj, leal j, gray a, patel r, feenstra t, palmer aj. evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth mount hood diabetes challenge. value in health 2020.

2019

ramos m, foos v, ustyugova a, hau n, gandhi p, lamotte m. cost-effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease. diabetes therapy 2019.
kent s, becker f, feenstra t, tran-duy a, schlackow i, tew m, zhang p, ye w, lizheng s, herman w, mcewan p, schramm w, gray a, leal j, lamotte m, palmer a, willis m, clarke p. the challenge of transparency and validation in health economic decision modelling: a view from the mountain top. pharmacoeconomics 2019.
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, amarenco p, annemans l patient and caregiver productivity loss and indirect costs associated with cardiovascular events in europe. european journal of preventive cardiology. doi: 10.1177/2047487319834770.
lau e, salem a, chan jcn, so wy, lim mct, ngai w, kong a, lamotte m, luk a. insulin glargine compared to neutral protamine hagedorn (nph) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in hong kong: a cost-effectiveness analysis. cost effectiveness and resource allocation 2019.
goodall g, lamotte m, ramos m, maunoury f, pejchalova b, de pouvourville g. cost-effectiveness analysis of the sapien 3 tavi valve compared with surgery in intermediate-risk patients. j med economics 2019. 2019, vol. 22, no. 4, 289-296.
ramos m, lamotte m, gerlier l, svangren p, miquel-casas a, haughney j. the cost-effectiveness of physical activity in the management of copd patients in the uk. international journal of copd 2019:14 227-239.

2018

foos v, wang k, mcewan p, zhang y, xin p, jiang x, qu s, xiong t, de moor r, ramos m, lamotte m, ji l. assessing the burden of type 2 diabetes in china considering the current status-quo management and implications of improved management using a modeling approach. value in health regional issues. volume 18, may 2019, pages 36-46.
rodríguez-zapeda m, gonzález l, bravo a, pompa t, silva s, paredes r, garcía j, ramos m, wikinson l, lamotte m. cost-effectiveness of rfviia versus pd-apcc in the management of mild to moderate bleeds in pediatric patients with hemophilia a with inhibitors in mexico. value health reg issues. 2018 oct 11;17:164-173. doi: 10.1016/j.vhri.2018.06.007.
s pinar bilir, richard hellmund, elizabeth wehler, huimin li, julie munakata, mark lamotte. the cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in sweden. european endocrinology, 2018;14(2):80-5.
s pinar bilir, richard hellmund, elizabeth wehler, huimin li, julie munakata, mark lamotte. cost- effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in sweden. european endocrinology, 2018;14(2):73-9.
palmer aj, si l, tew m, hua x, willis ms, asseburg c, mcewan p, leal j, gray a, foos v, lamotte m, feenstra t, o'connor pj, brandle m, smolen hj, gahn jc, valentine wj, pollock rf, breeze p, brennan a, pollard d, ye w, herman wh, isaman dj, kuo s, laiteerapong n, tran-duy a, clarke p. computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge. value in health 2018.
l. martins, p. amaro, s. pessanha, m. guerra, j. machado, m. l. carvalho, and j. p. santos. multiconfiguration dirac-fock calculations of zn k-shell radiative and nonradiative transitions. x-ray spectrometry. 2019; 49:192-199.
s. pessanha, s. silva, l. martins, j. p. santos, and j. m. silveira, suitability of the compton-to- rayleigh ratio in x-ray fluorescence spectroscopy: hydroxyapatite-based materials characterization. journal of analytical atomic spectrometry. 2019; 34(5):854-859

2017

decuypere f, sermon j, geerts p, denee tr, de vos c, malfait b, lamotte m, mulder cl. treatment continuation of four long-acting antipsychotic medications in the netherlands and belgium: a retrospective database study. plos one. 2017 jun 14;12(6):e0179049. doi: 10.1371/journal.pone.0179049. ecollection 2017.
gerlier l, lamotte m, grenèche s, lenne x, carrat f, weil-olivier c, damm o, schwehm m, eichner m. assessment of public health and economic impact of intranasal live-attenuated influenza vaccination of children in france using a dynamic transmission model. appl health econ health policy. 2017 apr;15(2):261-276. doi: 10.1007/s40258-016-0296-4.
p. amaro, j. p. santos, a. samouco, r. adão, l. martins, s. weber, s. tashenov, m. l. carvalho, s. pessanha. validation of the geant4 monte carlo package for x-ray fluorescence spectroscopy in triaxial geometry. spectrochimica acta part b: atomic spectroscopy. 2017; 130:60-66
m, fonseca, r. mateus, c. santos, j. cruz, h. silva, h. luis, l. martins, a. p. jesus. quantitative analysis of li by pige technique. nuclear instruments and methods in physics research section b: beam interactions with materials and atoms. 2017; 406:144-147

2016

gerlier l, lamotte m, dos santos mendes s, damm o, schwehm m, eichner m. estimates of the public health impact of a paediatric vaccination programme using an intranasal tetravalent live- attenuated influenza vaccine in belgium. paediatr drugs. 2016 jun 7.pp 1-16. doi 10.1007/s40272- 016-0180-6.
de francesco m, lamotte m, ascierto pa, di rienzo p, asukai y. economic evaluation of ipilimumab in first line treatment of advanced melanoma in italy. global & regional health technology assessment. doi: 10.5301/grhta.5000230.
ramos m, haughney j, henry n, lindner l, lamotte m. the cost-utility of aclidinium bromide 400μg/formoterol fumarate dihydrate 12μg compared to aclidinium bromide 400μg alone in the management of moderate to severe chronic obstructive pulmonary disease. clinicoeconomics and outcomes research 2016:8 445-456.
m. streicher, v. corregidor, n. catarino, l.c. alves, n. franco, m. fonseca, l. martins, e. alves, e.m. costa, b.a. dedavid. study of in distribution on gainsb: al crystals by ion beam techniques. nuclear instruments and methods in physics research section b: beam interactions with materials and atoms. 2016; 371:278-282.

2015

de francesco m, ronco c, wacinski pj, wessely r, hernández p, lamotte m. economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in germany, italy, poland and spain. the journal of medical economics.
chevalier p, vandebrouck t, de keyzer d, mertens a, lamotte m. cost and co-morbidities associated with hypoglycemic inpatients in belgium. the journal of medical economics, august 2015 doi: 10.3111/13696998.2015.1086775
jugrin av, ustyugova a, urbich m, de francesco m, lamotte m, sunderland t. indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a uk setting. the journal of medical economics, august 2015. doi: 10.3111/13696998.2015.1078340.
jugrin av, ustyugova a, urbich m, lamotte m, sunderland t. the cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute venous thromboembolism in the uk. thrombosis and haemostasis 2015; 114, issue 4. dx.doi.org/10.1160/th14-12-1027.

2014

mcewan p, foos v, palmer jl, lamotte m, lloyd a, grant d. validation of the ims core diabetes model. value health. 2014 sep;17(6):714-24. doi: 10.1016/j.jval.2014.07.007.
vellopoulou a, van agthoven m, van der kolk a, de knegt rj, berdeaux g, cure s, bianic f, lamotte m. cost-utility of telaprevir - peginterferon - ribavirin (pr) versus boceprevir - pr and versus pr alone in chronic hepatitis c in the netherlands. appl health econ health policy. 2014 dec;12(6):647-59. doi: 10.1007/s40258-014-0120-y
reynolds mr, lamotte m, todd d, khaykin y, eggington s, tsintzos s, klein g. cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. europace 2014 may;16(5):652-9. doi: 10.1093/europace/eut380. epub 2014 jan 2.
duran a, spaepen e, lamotte m, brosa m, gutiérrez l, restovic g. costes de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia inducida por quimioterapia en españa: resultados preliminares procedentes de la adaptación de un estudio belga. accepted for publication in pharmacoeconomics spanish research articles volume 11, pages15-23 (2014).

2013

chevalier p, lamotte m, joseph a, dubois d, boeckxstaens g. in-hospital costs associated with chronic constipation in belgium: a retrospective database study. neurogastroenterology and motility 2014 mar;26(3):368-76. doi: 10.1111/nmo.12269. epub 2013 dec 11.
max dratwa, anne-marie bogaert, koen bouman, xavier warling, remi hombrouckx, mario schurgers, pierre dupont, anne vereerstraeten, guy van roost, karin caekelbergh, mark lamotte and suzanne laplante. the economic burden of dialysis patients in belgium: a comparison between haemo and peritoneal dialysis. the e-book outcomes assessment in end - stage kidney disease measurements and applications in clinical practice. 2013 pp.208-222 (15)
chevalier p, lamotte m, van campenhout h, eyckerman r, annemans l. cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in belgium. j med econ 2013; 16:1-10.
palmer aj; mount hood 5 modeling group, clarke p, gray a, leal j, lloyd a, grant d, palmer j, foos v, lamotte m, hermann w, barhak j, willis m, coleman r, zhang p, mcewan p, betz brown j, gerdtham u, huang e, briggs a, carlsson ks, valentine w. computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. value health. 2013 jun;16(4):670-85. doi: 10.1016/j.jval.2013.01.002. epub 2013 apr 18.
body jj, chevalier p, gunther o, hechmati g, lamotte m. the economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in belgium. journal of medical economics 2013: 16 (5); 1-8.

2012

nevens f, colle i, michielsen p, robaeys g, moreno c, caekelbergh k, lamotte m, wyffels v. resource use and cost of hepatitis c-related care. eur j gastroenterol hepatol. 2012 oct;24(10):1191-8. doi: 10.1097/meg.0b013e3283566658.
grabbi e, lucioni c, duran a, spaepen e, lamotte m, kutikova l, pujol b, gozzo m, iannazzo s. analisi dei costi associati agli agenti stimolanti l’eritropoiesi nel trattamento dei pazienti con anemia indotta da chemioterapia in italia. pharmacoeconomics 2012: 14(2): 91-100.
duran a, spaepen e, lamotte m, walter e, umuhire d, lucioni c, pinheiro b, brosa m, kutikova l, pujol b, van bs, annemans l. cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five european countries. j med econ. 2012;15(3):409-18. doi: 10.3111/13696998.2011.653597. epub 2012 jan 13.

2010

gerlier l, lamotte m, wille m, dubois d, meurgay f, kreuz p, vanlauwe j. the cost-utility of autologous chondrocytes implantation using chondrocelect® in symptomatic knee cartilage lesions. pharmacoeconomics 2010; 28: 1129-1146.
gerlier l, lamotte m, awada a, bosly a, bries g, cocquyt v, focan c, henry s, lalami y, machiels jp, mebis j, straetmans n, verhoeven d, somers l. the use of chemotherapy regimens carrying a moderate-to high risk of febrile neutropenia and the corresponding management of febrile neutropenia in breast cancer and non-hodgkin’s lymphoma: a belgian expert survey. bmc cancer 2010; 10: 642.
lamotte m, maugars y, le lay k, taïeb c. health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in france. clin exp rheumatol 2010; 28 (suppl. 63): s64-s70.

2009

caekelbergh k, nikkels a, leroy b, verhaeghe e, lamotte m, rives v. photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes from a real-life study. journal of drugs in dermatology 2009; 8: 992-6.

2008

herregods mc, daubresse jc, michel g, lamotte m, vissers e, vandenhoven g. discovery benelux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. acta cardiologica 2008; 63: 493-9.
dendale p, hansen d, berger j, lamotte m. long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention. acta cardiologica 2008; 63: 451-6.
annemans l, rémy v, lamure e, spaepen e, lamotte m, muchada jp, largeron n. economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in belgium. journal of medical economics 2008; 11: 135-150.

2007

lamotte m, annemans l. coste-efectividad de la aspirina en la prevención cardiovascular. med clin monogr (barc). 2007;7(7):27-36
annemans l, lamotte m, clarys p, van den abeele e. health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. eur j cardiovasc prev rehabil. 2007 dec;14(6):815-24.
lamotte m, annemans l, bridgewater b, kendall s, siebert m. a health economic evaluation of concomitant surgical ablation for atrial fibrillation. eur j cardiothorac surg. 2007; 32(5): 702-710.
tsutani k, igarashi a, fujikawa k, evers t, kubin m, lamotte m, annemans l. a health economic evaluation of aspirin in the primary prevention of cardiovascular disease in japan. intern med. 2007;46(4):157-62.

2006

lamotte m, annemans l, kawalec p, zoellners y. a multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction. herz. 2006 dec;31 suppl 3:74-82.
annemans l, lamotte m, kubin m, evers t, verheugt fw. which patients should receive aspirin for primary prevention of cardiovascular disease? an economic evaluation. int j clin pract. 2006 sep;60(9):1129-37.
lamotte m, piñol c, brotons c, annemans l, guardiola e, evers t, kubin m. [health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease] rev esp cardiol. 2006 aug;59(8):807-15. spanish.
lamotte m, annemans l, kawalec p, zoellner y. a multi-country health economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. pharmacoeconomics. 2006;24(8):783-95.
lamotte m, annemans l, evers t, kubin m. a multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. pharmacoeconomics. 2006;24(2):155-69.

2005

lamotte m, annemans l, lamberts g, michielsen d, nicolas h, van cangh p, van erps p, massaer k, dinet j, vranckx k. [the cost of complicated acute urinary retention: a patient chart analysis in belgium] rev med liege. 2005 nov;60(11):875-81. french.
annemans l, cleemput i, lamotte m, mcneill a, hargreave t. the economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the uk: a 6-month analysis. bju int. 2005 sep;96(4):566-71.

2004

tarricone r, marchetti m, lamotte m, annemans l, de jong p. what reimbursement for coronary revascularization with drug-eluting stents? eur j health econ. 2004 dec;5(4):309-16.
palmer aj, annemans l, roze s, lamotte m, rodby ra, de alvaro f; grupo de estudio colaborativo idnt. [cost-efectiveness of ibersartan in type ii diabetic nephropathy with hypertension. a spanish perspective] nefrologia. 2004;24(3):231-8. spanish.
palmer aj, annemans l, roze s, lamotte m, lapuerta p, chen r, gabriel s, carita p, rodby ra, de zeeuw d, parving hh. cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ace inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. diabetes care. 2004 aug;27(8):1897-903.
palmer aj, annemans l, roze s, lamotte m, rodby ra, bilous rw. an economic evaluation of the irbesartan in diabetic nephropathy trial (idnt) in a uk setting. j hum hypertens. 2004 oct;18(10):733-8.
palmer aj, annemans l, roze s, lamotte m, rodby ra, ritz e. [health economic consequences of the use of irbesartan in patients in germany with type 2 diabetes, nephropathy and hypertension] dtsch med wochenschr. 2004 jan 2;129(1-2):13-8. german.

2003

palmer aj, annemans l, roze s, lamotte m, rodby ra, cordonnier dj. an economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost- effectiveness of irbesartan in diabetic nephropathy trial (idnt) in the belgian and french settings. nephrol dial transplant. 2003 oct;18(10):2059-66.
annemans l, lamotte m, levy e, lenne x: cost-effectiveness of clopidogrel versus aspirin in patients with atherothrombosis based on the caprie trial. j med economics 2003; 6: 55-68.
annemans l, moeremans k, lamotte m, garcia conde j, van den berg h, myint h, pieters r, uyttebroeck a. incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-hodgkin's lymphoma in four european countries. leuk lymphoma. 2003 jan;44(1):77-83.
annemans l, moeremans k, lamotte m, garcia conde j, van den berg h, myint h, pieters r, uyttebroeck a. pan-european multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. support care cancer. 2003 apr;11(4):249-57. epub 2003 feb 4.
lamotte m, caekelbergh k, annemans l. dépistage de la bronchopneumopathie obstructive. ibes (institut belge de l'économie de la santé). briefing, n°40, bruxelles, janvier 2003, 6 pages

2002

caekelbergh k, lamotte m, annemans l. corticosteroïdes à inhaler chez des enfants asthmatiques. ibes (institut belge de l'économie de la santé). briefing, n°39, bruxelles, décembre 2002, 5 pages.
caekelbergh k, lamotte m, annemans l. épidemiologie et coût de l'asthme et de la broncho- pneumopathie chronique obstructive en belgique, ibes (institut belge de l'économie de la santé). briefing, n°38, bruxelles, novembre 2002, 5 pages.
lamotte m, annemans l, lefever a, nechelput m, masure j. a health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. diabetes care. 2002 feb;25(2):303-8.

2000

m. lamotte, h. debel, p. dodion: prophylaxie des pathologies thrombo-emboliques veineuses à l'aide d'une héparine de bas poids moléculaire en chirurgie orthopédique: résultats et analyses complémentaires d'un registre de surveillance épidémiologique. louvain med 2000; 119: 67-77..

1997

p. dendale, a. aerts, p. melis, m. lamotte: echocardiogram van de maand: acuut hartfalen bij een jonge vrouw. tijdschr cardiol. jaargang 9, nr. 6, juni 1997: 124-5.
m. lamotte, d. schoors, p. block: misleidende st- optrekkingen. tijdschr cardiol. jaargang 9, nr. 3, maart 1997.

1995

m. lamotte, m. kockx, m. hautekeete, j. holvoet, h. hubens: biliary phytobezoar: a medical curiosity. american journal of gastroenterology, vol. 90. aug. 95.

posters, abstracts and workshops

2024

Martins L, Ramos M, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Cardiovascular Outcomes in Type 2 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 1 EE107 - Monday 10.30-13.00.
Lamotte M , Martins L, Ramos M. Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Cardiovascular Outcomes in Type 1 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 2 EE284 - Monday 16.00-19.00
Ramos M, Martins L, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Mortality in Type 2 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 4 EE619 - Tuesday 16.00-19.00
Martins L, Lamotte M, Ramos M. Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Risk of Recurrent Cardiovascular Events in a Population With and Without Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 5 EE779 - Wednesday 9.00-10.00
Ramos M, Martins L, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Mortality in Type 1 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 5 EE780 - Wednesday 9.00-10.00
Ramos M, Gerlier L, Uster A, Steubl D, Muttram L, Frankel AH, Lamotte M. Chronic kidney disease progression model: development and validation. Accepted AMCP 2024 New Orleans, LA, Apr. 15- Apr. 18, 2024. Encore presentation.
Anaya P, Chattarjee S, Al Rawashdh N, Uster A, Mazo AR, Ramos M, Gerlier L, Lamotte M. Clinical and economic outcomes of delaying initiation of empagliflozin in chronic kidney disease (CKD) management in the United States. Accepted AMCP 2024 New Orleans, LA, Apr. 15- Apr. 18, 2024.
ramos m, gerlier l, uster a, steubl d, muttram l, frankel ah, lamotte m. chronic kidney disease progression model: development and validation. accepted amcp 2024 new orleans, la, apr. 15- apr. 18, 2024. encore presentation.

2023

james altunkaya, xinyu li, talitha feenstra, mi jun keng, mark lamotte, phil mcewan, jianchao quan, harry smolen, william valentine, michael willis jose leal, philip clarke. estimating cross-model variability in estimates of cost-effectiveness for eleven diabetes health economic models: a mass replication exercise. ihea conference june 10, 2023, cape town south africa.
anaya p, chattarjee s, al rawashdh n, uster a, mazo ar, james altunkaya, xinyu li, talitha feenstra, mi jun keng, mark lamotte, phil mcewan, jianchao quan, harry smolen, william valentine, michael willis jose leal, philip clarke. estimating cross-model variability in estimates of cost-effectiveness for eleven diabetes health economic models: a mass replication exercise. ihea conference june 10, 2023, cape town south africa.
anaya p, chattarjee s, al rawashdh n, uster a, mazo ar, ramos m, gerlier l, lamotte m. cost- effectiveness analysis of empagliflozin versus standard of care (soc) in patients with chronic kidney disease (ckd) in the us. poster presentation at amcp nexus 2023 orlando, fl, oct. 16- oct. 19, 2023.
martins l, panchal m, ramos m, lamotte m. time in range as alternative to hba1c change in the iqvia core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee625
mørup mf, taieb v, willems d, rose m, lamotte m, gerlier l, thom h. the cost-effectiveness of a bimekizumab versus secukinumab treatment pathway in patients with active axial spondyloarthritis in scotland. value in health, volume 26, issue 11, s2 (december 2023). ee192
borges m, soares m, lamotte m, olivieri av, shukla s, freitas p, silva miguel l. assessing the cost- effectiveness of semaglutide 2.4 mg injection for chronic weight management in portugal. value in health, volume 26, issue 11, s2 (december 2023). ee277
uster a, ramos m, gerlier l, muttram l, steubl d, frankel ah, lamotte m. chronic kidney disease progression model (ckd-pm): development and validation. american society of nephrology (asn). abstract 3943697. november 3, 2023 from 10:00 am to 12:00 pm. poster board #: fr-po940
ramos m, gerlier l, uster a, aguirre ar, muttram l, frankel ah, lamotte m. cost-effectiveness of empagliflozin in chronic kidney disease (ckd) management in the uk. ispor eu copenhagen november 2023. value in health, volume 26, issue 11, s2 (december 2023) ee420.
martins l, panchal m, ramos m, lamotte m. update to the macrovascular submodels of the iqvia core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee319
martins l, panchal m, ramos m, lamotte m. comparing three indirect cost approaches in the iqvia core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee470
mørup mf, taieb v, willems d, rose m, lamotte m, gerlier l, thom h. the cost-effectiveness of a bimekizumab versus secukinumab treatment pathway in patients with active axial spondyloarthritis in scotland. value in health, volume 26, issue 11, s2 (december 2023). ee192
borges m, soares m, lamotte m, olivieri av, shukla s, freitas p, silva miguel l. assessing the cost- effectiveness of semaglutide 2.4 mg injection for chronic weight management in portugal. value in health, volume 26, issue 11, s2 (december 2023). ee277

2022

mallory farrar, milena anatchkova, richard auchus, carine courtillot, katelyn cutts, adrian dobs, diala el-maouche, henrik falhammar, andre lacroix, natalie taylor, philippe touraine, mark lamotte, conor o'donoghue, chuck yonan. treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: a modified delphi consensus study. accepted as a poster at amcp (2022 march 30-april 1) and abstract published in journal of managed care & specialty pharmacy (jmcp).
mark lamotte, john dipersio, david siegel, haddas meron, philip serlin, laetitia gerlier. cost- effectiveness analysis of motixafortide on top of g-csf for stem-cell mobilization for autologous bone marrow transplantation in patients with multiple myeloma. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual (ee56).
martins l, ramos m, lamotte m. contrasting three hba1c progression equations using the iqvia core diabetes model. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual (ee366).
martins l, ramos m, lamotte m. contrasting four type 2 diabetes cardiovascular risk equations for east asia using the iqvia core diabetes model. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual (ee262).
olivieri av, larsen s, luckevich m, chan k, lamotte m. the cost-effectiveness of subcutaneous semaglutide 2.4mg injection in the management of obesity in canada using the core obesity model. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual (ee464)
kobina quansah, kåre hansen, katalina chan, sergey muratov, shoghag khoudigian, mark lamotte. smart insulin pen caps versus standard of care: a canadian cost-effectiveness analysis. accepted as a short oral discussion with presentation number: 666 at the 58th easd annual meeting, 19 - 23 september 2022.
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1 diabetes using the iqvia core diabetes model. ispor 2022 november 9, 2022 vienna, austria area and virtual (ee649).
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1 diabetes using the iqvia core diabetes model. mount hood diabetes challenge malmo 2022, september 24.
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1 diabetes using the iqvia core diabetes model. ispor eu vienna 6-9 november 2022. ee649
m lamotte, j dipersio, ds siegel, h meron, and l gerlier. cost-effectiveness analysis of motixafortide versus plerixafor in stem cell mobilization for autologous transplantation in patients with multiple myeloma. oral poster at the american society of hematology dec 11 2022. new orleans. publication number: 4848

2021

lopes s, grand t, johansen p, lamotte m, olivieri av. exploring different ways to predict mortality in a cost-effectiveness model for obesity. accepted as a poster at the international diabetes federation (idf) congress 2021. 06-11 december.

2020

ramos m, monteiro s, olivieri av, lamotte m. contrasting three type 2 diabetes cardiovascular risk equations for east asia with ukpds82 using the iqvia core diabetes model. ispor us 2020 orlando. value in health, volume 23, issue 5, s1 (may 2020) code pdb56
ramos m, monteiro s, lamotte m. impact of using different types of hba1c progression in the iqvia core diabetes model. ispor us 2020 orlando value in health, volume 23, issue 5, s1 (may 2020) code pdb52.
monteiro s, ramos m, lamotte m. does including acute pancreatitis as a complication have an impact on cost-effectiveness analyses using the iqvia core diabetes model? ispor us 2020 orlando. value in health, volume 23, issue 5, s1 (may 2020) code pdb44.
kiri s, arteaga duarte ca, lee e, low r, tsakeu e, lamotte m, gerlier l. cost-effectiveness analysis of certolizumab pegol versus secukinumab and ixekizumab in non-radiographic axial spondyloarthritis in the u.s. amcp nexus 2020 virtual october 19.
kiri s, arteaga duarte c, lamotte m, gerlier l. budget impact analysis of a reduced maintenance dose of certolizumab pegol in patients with axial spondyloarthritis in the united kingdom. ispor europe 2020 virtual conference milano nov 16-19 abstract id# 107821.
cai r, eichner m, schwehm m, rajaram s, mould-quevedo j, lamotte m. cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in germany. results of a dynamic transmission modelling approach. ispor europe 2020 virtual conference milano nov 16-19 abstract id# 105463.
ehlers l, lamotte m, monteiro s, sandgaard s, holmgaard p, frary ec, staehr p, ejskjaer n. the cost-effectiveness of empagliflozin in type 2 diabetes in denmark, incorporating cardiovascular outcomes. ispor europe 2020 virtual conference milano nov 16-19 abstract id# 107114.
ramos m, monteiro s, lamotte m. does including egfr along to hba1c as a driver of treatment switch changes outcomes in cost-effectiveness analyses in type 2 diabetes? ispor europe 2020 virtual conference milano nov 16-19 abstract id# 108179.
mitsuo r, demiya s, tawseef a, de moor r, ramos m, lamotte m. the asian type 2 diabetes cardiovascular risk equations simulation using the iqvia core diabetes model. digital poster at the 63rd annual meeting of the japan diabetes society 2020.

2019

ramos m, foos v, ferrufino c, yu-isenberg k, lamotte m. the relationship between poor adherence and hba1c and weight changes in patients with type 2 diabetes. pdb116, november 2018, ispor europe 2018, barcelona, spain.
lamotte m, salem a, mettam s, ustyugova a, zhang yj, ramos m. projected long-term clinical benefit and cost-effectiveness of empagliflozin compared to glimepiride in patients with type 2 diabetes in china. ada scientific sessions 2019. san francisco 7-11 june. 1292-p.
monteiro s, ramos m, altrabsheh e, gurjar k, olivieri a, lamotte m. contrasting framingham risk equations in type 2 diabetes using the iqvia core diabetes model. ispor 24 th annual international meeting new orleans us, may 18-22 2019. pdb35
olivieri a, ramos m, monteiro s, altrabsheh e, gurjar k, lamotte m. contrasting three type 2 diabetes cardiovascular risk equations for east asia with ukpds82 using the iqvia core diabetes model. ispor 24 th annual international meeting new orleans us, may 18-22 2019. pdb26
ramos m, olivieri a, monteiro s, altrabsheh e, gurjar k, lamotte m. body mass index associated utility approaches in the iqvia core diabetes model. ispor 24 th annual international meeting new orleans us, may 18-22 2019. pdb23
gurjar k, ramos m, monteiro s, altrabsheh e, olivieri a, lamotte m. comparability of results using two alternative versions of the iqvia core diabetes model. submitted to ispor 24 th annual international meeting new orleans us, may 18-22 2019. pdb30
altrabsheh e, monteiro s, ramos m, gurjar k, olivieri a, lamotte m. association between cardiovascular disease risk factors and hypoglycaemic events in type 2 diabetes using the iqvia core diabetes model. ispor 24 th annual international meeting new orleans us, may 18-22 2019. pdb64.
monteiro s, ramos m, lamotte m. health economic effects of the updated foot ulcer submodel in the iqvia core diabetes model. ispor europe 2019 copenhagen. tuesday nov 5 2019. pdb17.
ramos m, monteiro s, altrabsheh e, lamotte m the clinical and economic impact of adding an adherence module to the iqvia core diabetes model. ispor europe 2019 copenhagen. tuesday nov 5 2019. pdb61.
farag a, abdel moety h, hassan l, pathak p, lamotte m, levorsen a. the cost- effectiveness of enoxaparin in the prevention of venous thromboembolism in patients undergoing major surgery in egypt. ispor europe 2019 copenhagen. monday nov 4 2019. psu18.
sekongo ym, asamoah-akuoko l, lamotte m, bah a, dierick k. health economic value of blood in ivory coast: the case of maternal bleeding. ispor europe 2019 copenhagen. wednesday nov 6 2019. pmd16.
owusu-ofori spo, asamoah-akuoko l, lamotte m, bah a, dierick k. health economic value of blood in ghana: the case of maternal bleeding. ispor europe 2019 copenhagen. monday nov 4 2019. pns62.
dierick k, lamotte m, owusu-ofori spo, sekongo ym, rajab ja, asamoah-akuoko l, magutu v, bah a health economic value of blood in sub-saharan africa: the case of maternal bleeding. ispor europe 2019 copenhagen. monday nov 4 2019. pns158.
magutu v, rajab ja, asamoah-akuoko l, lamotte m, bah a, dierick k. the value of blood in sub-saharan africa. ispor europe 2019 copenhagen. monday nov 4 2019. pns184.
cogle s., ramos m., taylor k., roberts p., martindale r. cost benefit analysis of parenteral nutrition delivered via three chamber bags versus hospital-compounded bags. asph summer meetings 2019 exhibitions (46-t)
l. martins, p. amaro, m. l. carvalho, j. p. santos. x-ray fluorescence analysis using a standardless method. exsa quantitative methods in x-ray spectrometry, almada, portugal, lisbon, 12-17 of may 2019, almada, portugal

2018

foos v, mcewan p, lamotte m. review and validation of cardiovascular risk prediction models in east asian populations. value health 2018; 21: s220
mafalda ramos, mark lamotte, laetitia gerlier, per svangren, anna miquel cases, john haughney. the cost-effectiveness of physical activity in the management of copd patients in the uk. ers 2018 international congress. paris. sunday sept 16 pa701.
salem a, ramos m, hu h, zhong h, lamotte m. the health economic impact of optimizing post- hospitalization management for an exacerbation in copd patients in china. ispor asia pacific 2018 8-11 september 2018. prs13.
salem a, hu h, ramos m, zhong h, lamotte m. the economic impact of optimized post- hospitalization management for an exacerbation in copd patients in china. prs31, november 2018, ispor europe 2018, barcelona, spain.
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. patient and caregiver productivity loss and indirect costs associated with cardiovascular events in europe. european heart journal, volume 39, issue suppl_1, 1 august 2018, ehy565.p2561
ramos m, volker f, ustyugova a, hau n, gandhi p, lamotte m. cost-effectiveness analysis of empagliflozin in comparison to standard of care, sitagliptin and saxagliptin based on cardiovascular outcome trials. easd 2018. berlin october 2. poster 863.
ramos mafalda, volker foos, kristina yu-isenberg, mark lamotte. the relationship between poor adherence and hba1c and weight changes in patients with type 2 diabetes. mount hood diabetes challenge 2018. oct 6 abstract session 5.
mark lamotte, volker foos, anastasia ustyugova, nikco hau, pranav gandhi, mafalda ramos cost- effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials. mount hood diabetes challenge 2018. oct 6 abstract session 5.
de francesco m, lopes s, meincke hh, vega g, lean m, lamotte m. core obesity model to assess the cost-effectiveness of weight management interventions. ispor europe 2018 barcelona, spain. november, 2018. psy104.
ramos m, foos v, ustyugova av, hau n, gandhi p, lamotte m. cost-effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials. ispor europe 2018 barcelona, spain. november, 2018. (ce1-podium presentation)
lamotte m, ramos m, salem a, ustyugova av, hau n, gandhi p, foos v. cost-effectiveness analysis of empagliflozin in comparison to liraglutide based on cardiovascular outcome trials. pdb76.
dudek dz, lamotte m, sawicka m, huczek zj, depukat r, rajtar-salwa r, krupiarz m, duma k, sidelnikov e. the 1-year productivity loss and indirect costs after acute cardiovascular events in poland. pcv62, november 2018, ispor europe 2018, barcelona, spain.
salem a, ramos m, hu h, zhong h, lamotte m. the economic impact of optimized post- hospitalization management for an exacerbation in copd patients in china. prs31, november 2018, ispor europe 2018, barcelona, spain.
l martins, s pessanha, p amaro, m l carvalho, j p santos. monte carlo simulation of an edxrf setup with triaxial geometry: using rayleigh to compton ratio to evaluate the mean atomic number of unknown samples. european conference on x-ray spectrometry. 24–29 june 2018, ljubljana, slovenia
s pessanha, s silva, l martins,m l carvalho. taking advantage of compton-to-rayleigh ratio in edxrf spectra to recognize hydroxyapatite-based materials. european conference on x-ray spectrometry. 24-29 june 2018, ljubljana, slovenia
â. andrade, o. bezerra, i. queralt, s. diez, v. neves, w. souza, s. pessanha, l. martins, m. l. carvalho, j. d. fabris, d. guimarães. quantitative assessment of mercury and other heavy metals on freshwater fish and vegetation collected in areas of gold mining in brasil. european conference on x- ray spectrometry. 24-29 june 2018, ljubljana, slovenia
l. martins, p. amaro, m. l. carvalho, j. p. santos. método de análise por fluorescência de raios-x sem recurso a padrões. física 2018, 21ª conferência nacional de física, 28º encontro ibérico para o ensino da física, 2018, covilhã, portugal.

2017

foos v, lamotte m, mcewan p, jiang x, zhang yl, qu s, de moor r, ramos m, xiong t, wang k. assessing the economic burden of type 2 diabetes in china reflecting the current standard of the disease management and for improved management scenarios using a modeling approach. ispor 22nd annual international meeting boston, ma, usa may, 2017 pdb40.
mcewan p, foos v, lamotte m. approaches to standardising cardiovascular risk equation endpoints in order to facilitate their inclusion within a type 2 diabetes model. ispor 22nd annual international meeting boston, ma, usa may, 2017 prm69
foos v, lamotte m, altrabsheh e, sathananthan a, mcewan p. determinants of the relationship between improved glucose control and modeled health outcomes in type 2 diabetes simulation models. ispor 20th annual european congress glasgow, scotland november, 2017 prm91
foos v, lamotte m, sathananthan a, altrabsheh e, mcewan p. exploration of run-time requirements in probabilistic sensitivity analysis utilizing a patient level based type 2 diabetes simulation model. ispor 20th annual european congress glasgow, scotland november, 2017 prm101
gerlier l, sidelnikov e, kutikova l, lamotte m, amarenco p, kotseva k, annemans l. interim results of a multi-country survey to evaluate productivity loss and indirect costs after cardiovascular events in europe. ispor 20th annual european congress glasgow, scotland november, 2017. cv1
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. work productivity losses in the year following acute coronary syndrome or stroke: interim results of a multi- country survey in europe. american heart association (aha) scientific sessions 2017, anaheim, california, usa (m2005).
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. work productivity losses in the year following acute coronary syndrome or stroke: interim results of a multi- country survey in europe. american heart association (aha) scientific sessions 2017, anaheim, california, usa (m2005).
foos v, mcewan p, lamotte m. comparison of cost-effectiveness acceptability curves (ceac) in modeled analyses with and without established heterogeneity of patient characteristics. ispor 22nd annual international meeting boston, ma, usa may, 2017 prm72.
willis m, feenstra t, lamotte m, brennan a. comparing, contrasting, and validating health economic decision models: experiences from the latest mt. hood challenge in diabetes and lessons for other disease areas. ispor 20th annual european congress glasgow, scotland november, 2017. workshop 17.
l martins, s pessanha, p amaro, m l carvalho, j p santos. monte carlo simulation of an edxrf setup with triaxial geometry: using rayleigh to compton ratio to evaluate the mean atomic number of unknown samples, 11th joint iberian meeting on atomic and molecular physics (iber) 2017, barcelona, spain
l. martins. x-ray fluorescence analysis using a standardless method. 2nd doctoral congress in engineering, dce 2017, oporto, portugal

2016

mcewan p, gordon j, foos v, lamotte m, evans m, paldánius pm. estimating the cost-effectiveness of vildagliptin versus sulfonylurea in combination with metformin: clinical guidelines versus clinical practice. ispor 21 st annual international meeting – washington 2016. presentation code: pdb31.
mcewan p, gordon j, foos v, lamotte m, evans m, paldánius pm. cost-effectiveness of type 2 diabetes treatments in middle eastern countries: an economic evaluation of the edge study using patient level data. ispor 21st annual international meeting, washington, dc, may 21-25 2016. pdb32.
foos v, lamotte m, mcewan p. the comparison of cardiovascular incidence predictions in type 1 diabetes utilizing alternative risk prediction models. ispor 21st annual international meeting, washington, dc, may 21-25 2016. prm85
foos v, lamotte m, mcewan p. appropriate allocation of time horizons for lifetime modeling projections in type 2 diabetes may improve the precision of cost effectiveness evaluations. ispor 21st annual international meeting, washington, dc, may 21-25 2016. prm91.
foos v, lamotte m, mcewan p. comparing direct and indirect cost of type 2 diabetes individuals across three age ranges in the us. ispor 21st annual international meeting, washington, dc, may 21-25 2016. prm92
mcewan p, foos v, lamotte m, evans m. quantifying the health economic benefit of key therapeutic outcomes in the management of type 2 diabetes and assessing their inter-relationship. ispor 21st annual international meeting, washington, dc, may 21-25 2016. prm95.
de francesco m, johnson p, lamotte m. cost-effectiveness of allogenic pancreatic islet transplantation versus whole pancreas transplantation in england and wales. ispor 21st annual international meeting, washington, dc, may 21-25 2016. pdb42.
todoran tm, goldfarb s, peña cs, ferrufino cp, stacey kowal s, de francesco m, lamotte m, king a. budget impact of contrast media choice and contrast induced acute kidney in high-risk patients undergoing invasive coronary angiography with or without percutaneous coronary intervention from a us hospital perspective. ispor 21st annual international meeting, washington, dc, may 21-25 2016. pmd14.
foos v, lamotte m, mcewan p. appropriate time horizons for modelling in type 2 diabetes may improve the precision of economic evaluation. ada scientific sessions 2016. publication number 356-or. monday jun 13, 2016 4:30 pm - 6:30 pm. oral presentation.
foos v, lamotte m, mcewan p. comparing direct and indirect costs of type 2 diabetes across three age ranges in the u.s. ada scientific sessions 2016. publication number 112-or. saturday jun 11, 2016 1:45 pm - 3:45 pm. oral presentation.
de francesco m, lamotte m, johnson p. cost-effectiveness of pancreatic islet transplantation vs. whole pancreas transplantation in the uk. ada scientific sessions 2016. publication number 180- or. saturday jun 11, 2016 4:00 pm - 6:00 pm. oral presentation.
mcewan p, foos v, lamotte m, evans m. characterising the health economic benefit of key therapeutic outcomes in the management of type 2 diabetes. ada scientific sessions 2016. poster: 1251-p.
mcewan p, foos v, lamotte m. replacing input probability distributions with mean values can bias simulation output: an illustration using the core diabetes model. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. prm 85.
foos v, mcewan p, lamotte m. implications of introducing patient heterogeneity in cost effectiveness modeling. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. prm 81.
chevalier p, van gils c, lamotte m. description of first-line treatments in patients with non-resectable colorectal cancers in belgium. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. pcn 233.
chevalier p, van gils c, lamotte m. in-hospital mortality and complications following surgical resection of glioblastoma. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. pcn 45.
ramos m, lamotte m, chevalier p, goodall g. assessing the cost-effectiveness of transcatheter aortic valve implantation in inoperable patients with severe aortic stenosis in uk. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. pmd 70.
chevalier p, lamotte m. hospital resources and co-morbidities associated with crohn's disease and ulcerative colitis in belgium. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. pgi 13.
chevalier p, tsakeu e, lamotte m. epidemiology of patients receiving hematopoietic stem cell patients in belgium. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. psy 159.
caekelbergh k, chevalier p, lamotte m, kutikova l, schutyser e, annemans l. short and long term costs associated with different cardiovascular events in belgium. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. php 108.
gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l. rationale and design of a multi-center survey to evaluate productivity losses and indirect costs after cardiovascular events in europe. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november 2016. prm 216.

2015

portilla c, gonzalez a. f, cortés j m, castro a., sterling sp., ramos m. the cost-effectiveness of pd- apcc versus rfviia in pediatric patients with haemophilia type a and inhibitors with mild to moderate joint bleeding in colombia. isth 2015 congress. june 20-25. (abs-1196)
ramos m, nivelle e, lamotte m, ehm a: assessing the cost-effectiveness of using 3chamber bags compared to hospital compounded bags and separate bottle systems for hospitalized patients requiring parenteral nutrition. 11th world congress: "de gustibus disputandum non est!" health economics and nutrition: an ihea world congress. milan june 2015.
soto j, gonzález l, bravo a, bergés a, pompa, rodriguéz m, silva s, paredes r, lamotte m. the cost-effectiveness of pd-apcc versus rfviia in pediatric patients with haemophilia a and inhibitors with mild to moderate joint bleeding in mexico. isth15abs-3646. po355-wed. isth conference toronto june 24 2015.
lovato e, warburton m, mcewan p, lamotte m, foos v. the importance of appropriately incorporating the effects of hypoglycaemia within a health economic model when hypoglycaemia rates are high. easd conference stockholm 2015 abstract # 52.
m. lamotte, v. foos, p. mcewan. contrasting eight cardiovascular risk equations for use in type 2 diabetes cohorts using the core diabetes model. stockholm 2015 abstract #1159
ramos m, caekelbergh k, lamotte m. the economic burden of poor adherence to statins in belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pcv169
chevalier p, lamotte m. an epidemiological evaluation of the incidence of deep venous thrombosis and pulmonary embolism in patients with hip or knee replacement surgery and of its impact on the average length of stay and hospitalization cost. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pcv85.
chevalier p, lamotte m. an epidemiological evaluation of the impact of percutaneous coronary interventions on the hospitalization cost, length of stay and mortality of patients hospitalized with acute coronary syndromes. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pcv91.
ramos m, brouyère s, caekelbergh k, lamotte m. the economic consequences of the use of antidepressants in belgium: prescribing behavior and misuse of antidepressants. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pmh48.
caekelbergh k, ramos m, lamotte m. the economic consequences of the use of antidepressants in belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pmh49.
lamote m. caekelberg k. ramos m. ims health report. appropriate use of medicines in the belgian health-care context (2015)
ramos m, haughney j, henry n, lindner l, lamotte m. assessing the cost-effectiveness of using aclidinium bromide 400 μg /formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg in the management of moderate to severe chronic obstructive pulmonary disease. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. ce4.
caekelbergh k, ramos m, lamotte m. the economic consequences of the use of antibiotics in belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. php132.
ramos m, caekelbergh k, lamotte m. avoidable hospitalizations due to medication errors in belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. php136.
gerlier l, lamotte m, dos santos s, schwehm m, eichner m. public health outcomes of paediatric influenza vaccination with an intranasal tetravalent live attenuated vaccine in belgium using a dynamic transmission model ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pin9.
chevalier p, lamotte m. hospitalization cost and length of stay associated with ophthalmological surgery depending on the diabetic status. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pdb40.
gerlier l, lamotte m, chevalier p. assessing the burden of systemic lupus erythematosus in belgium using a longitudinal hospital records database. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. psy51.
foos v, lamotte m, mcewan p. contrasting predictions of cardiovascular incidence derived from alternative risk prediction models in type 1 diabetes. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm72.
foos v, lamotte m, mcewan p. contrasting model predicted life expectancy in patients with type 2 diabetes across different mortality risk prediction models versus data from the canadian chronic disease surveillance system. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm74.
mcewan p, foos v, lamotte m. the importance of accounting for baseline hypoglycaemia frequency when modelling hypoglycaemia disutility in type 1 diabetes mellitus. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm84.
mcewan p, foos v, lamotte m.validating approaches to modelling end-stage renal disease using the ims core diabetes model. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm85.
mcewan p, foos v, lamotte m. the impact of baseline hba1c and hba1c trajectories on time to therapy escalation in type 2 diabetes mellitus. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm88.
mcewan p, foos v, lamotte m. investigating the impact of contemporary risk factors for diabetes complications and their evolution on risk prediction using the ukpds 82 equation. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm98.
p mcewan, m evans, m lamotte, v foos. assessing the relative contribution to changes in quality-adjusted life expectancy associated with hba1c, weight and hypoglycaemia across multiple risk equations with the core diabetes model (cdm) ispor 20th annual international meeting - philadelphia 2015. presentation code: prm74
p mcewan, m lamotte, v foos. impact of single risk factor changes on long-term outcomes and cost in a type 2 diabetes modeling study contrasting projections with ukpds68, swedish national diabetes registry and the advance risk equations. ispor 20th annual international meeting - philadelphia 2015. presentation code: prm37
v foos, m lamotte, p mcewan. contrasting the relative risk reduction of cardiovascular events in the core diabetes model associated with single risk factor changes across alternative risk engines: ukpds68, ukpds82 and swedish national diabetes registry equations ispor 20th annual international meeting - philadelphia 2015. presentation code: prm73
volker foos, mark lamotte, phil mcewan. contrasting cost-effectiveness results derived from contemporary sets of alternative risk equations in type 2 diabetes ispor 20th annual international meeting - philadelphia 2015. presentation code: prm23
jugrin av, ustyugova av, lamotte m, sunderland tj. the costeffectiveness of dabigatran etexilate compared with edoxaban in the treatment of acute venous thromboembolism in the uk. ispor 20th annual international meeting - philadelphia 2015. presentation code: pcv78
c. santos, m. guerra, m. fonseca, v. corregidor, l. c. alves, h. silva, a. costa, l. martins, h. luis, m. l. carvalho. measurement of the ca/p ratio of healthy bone samples by micro-pixe, pige, and micro-xrf. 22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
m. streicher, v. corregidor, n. catarino, l.c. alves, n. franco, m. fonseca, l. martins, e. alves, e.m. costa, b.a. dedavid. study of in distribution on gainsb: al crystals by ion beam techniques . 22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
a. f. silva, m. guerra, c. santos, m. c. carvalho, a. costa, l. martins, m. l. carvalho, j. p. santos, m. capelão, m. fonseca. a study of trace elements in canine elbow dysplasia by pige and xrf. 22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
m. fonseca, l. martins, a. p. jesus. erya profiling: a code for depth profiling of light elements in inhomogenous sample by pige. 22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia

2014

lamotte m, gerlier l, caekelbergh k, lalji k, polifka j, lee e. impact of a pharmacological cardioversion with vernakalant on the management cost of recent atrial fibrillation in belgium. ispor amsterdam 2014. pcv103.
gerlier l, weil-olivier c, carrat f, lenne x, lamotte m, greneche s, eichner m. public health and economic impact of vaccinating children with a quadrivalent live attenuated influenza vaccine in france using a dynamic transmission model. ispor amsterdam 2014. pin61
chevalier p, de beule j, lamotte m, hunsche e, régulier e. cost of a pulmonary arterial hypertension-related hospitalization in belgium. ispor amsterdam 2014.
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. the cost-effectiveness of dabigatran etexilate compared with warfarin in the treatment and secondary prevention of acute venous thromboembolism in the uk. ispor amsterdam 2014. pcv98
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. cost-effectiveness of dabigatran etexilate compared with rivaroxaban in the treatment of acute venous thromboembolism in the uk. ispor amsterdam 2014. pcv95
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. the cost-effectiveness of dabigatran etexilate compared with warfarin and rivaroxaban in the treatment of acute pulmonary embolism in the uk. ispor amsterdam 2014. pcv96
lamotte m, wyffels v, knudsen ms, troelsgaard a, hemels m. health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in belgium [internet]. vol. 17, value in health. 2014. p. a248. a
foos v, mcewan p, lamotte m, grant d. all-cause mortality validation of the core diabetes model against predictions of the charlson comorbidity index. ispor amsterdam 2014. prm87.
mcewan p, grant d, lamotte m, foos v. quantifying nonlinear effects in stochastic markov simulation using ukpds 68 and ukpds 82 equations in type 2 diabetes modeling analysis with the ims core diabetes model (cdm). ispor amsterdam 2014. prm17.

2013

ramos m, vellopoulou k, lamotte m, chang cj, carr e. a health economic evaluation of fenofibric acid in combination with statins in the prevention of cardiovascular disease in taiwanese mixed hyperlipidemia patients. value in health. 2013. vol. 16, issue 7, page a526. ispor 16 th annual european congress
beaudet a., grabbi e., maurel f., >m. ramos, lebioda a. review of cost of diabetes complications in four european countries. ispor 16 th annual european congress, dublin (pdb71)
gil f. r, ramos m. análisis de costes de los tratamientos para la maduración cervical e inducción al parto. x reunión de la sociedad de obstetricia y ginecología de la comunidad valenciana. 2013.
matthew reynolds, mark lamotte, derick todd, yaariv khaykin, simon eggington, stelios tsintzos, gunnar klein. cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. boston atrial fibrillation symposium jan 2013. poster 29. abstract in journal of cardiovascular electrophysiology.
lamotte m, chevalier p, vandebrouck t. the burden of hospitalizations due to insulin related hypoglycemia in belgium. ispor 18th annual international meeting - new orleans 2013. pdb33
mcewan p, foos v, grant d, lamotte m, palmer jl, lloyd a.drivers of cost-effectiveness in type-2 diabetes mellitus. ispor 18th annual international meeting – new orleans 2013. pdb53
mcewan p, lamotte m, grant d, palmer jl, lloyd a, foos v. assessing the consistency of absolute cardiovascular risk prediction and relative risk reduction in type- 2 diabetes mellitus. ispor 18th annual international meeting – new orleans 2013. pdb54
mcewan p, foos v, grant d, palmer jl, lamotte m, lloyd a. do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type-2 diabetes? ispor 18th annual international meeting – new orleans 2013. pdb55
foos v, mcewan p, grant d, palmer jl, lamotte m, lloyd a. the cost and productivity consequences of non-severe hypoglycaemic episodes (nshe) in patients treated with sulfonylurea or dpp4 dual combination oral therapy. ispor 18th annual international meeting - new orleans 2013. pdb57
chevalier p, lamotte m, rigney u, engstrom g, emmas c. impact of initiating statin therapy at a high dose - a retrospective observational study populations in the united kingdom. ispor 18th annual international meeting – new orleans 2013. pcv14
jugrin av, lamotte m, malfait m, vandebrouck t. the cost-utility of insulin degludec compared with current standard of care in the management of type one and type two diabetes mellitus in belgium. ispor dublin 2013 number 45328.
jugrin av, caekelbergh k, vanacker j, vancauwenberghe l, lamotte m. the cost-utility of catheter-based renal denervation as compared to current standard of care for resistant hypertension in belgium. ispor dublin 2013 number 46042.
caekelbergh k, gerlier l, lamotte m, kinoo d, meurgey f, berdeaux g. the current management and costs of irritable bowel syndrome with constipation in belgium: a 2-round expert survey. ispor dublin 2013 number 44901.
gerlier l, caekelbergh k, lamotte m, kinoo d, meurgey f, berdeaux g cost-utility analysis of linaclotide in the treatment of irritable bowel syndrome with constipation in belgium. ispor dublin 2013 number 44843.
vandekerckhove s, lamotte m, petit c. cost-minimization analysis of ferumoxytol in the management of anemia in patients with chronic kidney disease in belgium. ispor dublin 2013 number 46180.
lamotte m, vellopoulou k, richir k, smets j, grabe k, coppens k. the cost-utility of fidaxomicin as compared to current standard treatment in the management of clostridium difficile infections in belgium. ispor dublin 2013 number 44107.

2012

a duran, e spaepen, m lamotte, d eheberg, a jugrin, l kutikova, b pujol, e kunz, l annemans. cost of erythropoiesis-stimulating agents (esas) in the treatment of chemotherapy-induced anaemia in germany. 17th congress of the european association of hospital pharmacists, 21-23 march 2012, vienna.
nivelle e, mathou f, lamotte m. assessing the budget impact of using scanbag® in ct in 6 european countries. ispor us conference june 3-8 2012, washington dc. pmd13
gerlier l, midy f, lièvre m, maurel f, cohn e, vellopoulou k, lamotte m. assessing the cost- effectiveness of the recommended antihypertensive drug classes in france using a lifetime markov model. ispor us conference june 3-8 2012, washington dc. cvd46.
gerlier l, midy f, lièvre m, maurel f, cohn e, vellopoulou k, lamotte m. a lifetime cost-effectiveness analysis of the recommended antihypertensive drug classes in france. 9th htai annual meeting. hta in integrated care for a patient centered system, bilbao from 23 to 27 june 2012. poster 363
lamotte m, chevalier p, foos v, mcewan p, lloyd a, palmer j, grant d. the cost of diabetes complications in belgium. the mount hood six challenge. baltimore, usa june 7 and 8 2012. conference session 2. june 7 1.30, first presentation.
holtzer-goor k, van de kerckhove s, van den steen d, van megen y, huijgens p, lamotte m, uyl-de groot c. modelling the 10-year cost-effectiveness of bendamustine as first line treatment for chronic lymphocytic leukaemia in the netherlands. 17 th eha conference amsterdam 14-17 june 2012. poster 1089.
palmer jl, caputo j, foos v, grant d, lamotte m, lloyd a, mcewan p. direct medical costs of diabetes mellitus in china: annual cost of illness and long-term projections using a validated diabetes model. ispor asia conference sept 2-4 2012. sept 4 2012.
tham cc, leung ck, li fc, gerlier l, lamotte m, caputo j, tan r. new formulation of travoprost reduces dry eye occurrence and costs in glaucoma patients: model-based results for hong kong. ispor asia conference sept 2-4 2012. pss5. sept 3 2012
gerlier l, lamotte m, caputo j, tan r. the cost-effectiveness of travoprost preserved with polyquad® in newly treated open-angle glaucoma patients in 7 asian countries. ispor asia conference sept 2-4 2012. pss4. sept 3 2012.
gerlier l, lamotte m, caputo j, tan r. medical resource use and associated costs in open-angle glaucoma in 10 asia-pacific countries. ispor asia conference sept 2-4 2012. pss3. sept 3 2012.
caekelbergh k, lamotte m. evaluation of real life use of sugammadex for decurarization of neuromuscular blockade in surgical interventions in belgium. ispor europe conference nov 3-7 2012. php87. nov 5 2012.
chevalier p, black cm, lamotte m, crombach j, huismans j, rosiek r, fan t. frequency of administration of biologics has an impact on treatment decision making. ispor europe conference nov 3-7 2012. pms58. nov 6 2012.
chevalier p, lamotte m, petit c. cost-effectiveness of ticagrelor in the management of acute coronary syndromes in belgium. ispor europe conference nov 3-7 2012. pcv64. nov 5 2012.
gerlier l, vellopoulou k, lamotte m, lacey l, carr e. a health economic evaluation of omega-3 acid ethyl esters 90 in the secondary prevention post-mi. ispor europe conference nov 3-7 2012. pcv65. nov 5 2012.
lamotte m, chevalier p. the cost of diabetes complications in belgium. ispor europe conference nov 3-7 2012. pcv32. nov 5 2012.
lamotte m, gerlier l, chevalier p. the burden of diabetes mellitus in belgium: a retrospective database study. ispor europe conference nov 3-7 2012. pcv19. nov 5 2012.
vandekerckhove s, lamotte m, iannazzo s, chirita o. cost utility analysis of bortezomib in a biomarker positive subgroup of relapsed and refractory folicular lymphoma. ispor europe conference nov 3-7 2012. pcn100. nov 6 2012.
vandekerckhove s, holtzer-goor k, van den steen d, van megen y, huijgens p, lamotte m, uyl- de groot c. cost effectiveness analysis of bendamustine as first line treatment for chronic lymphocytic leukaemia in the netherlands. ispor europe conference nov 3-7 2012. pcn90. nov 6 2012.
vellopoulou a, van agthoven m, vanderkolk a, lamotte m, cure s, bianic f. the cost-utility of telaprevir in combination with peginterferon alpha and ribavirin (pr) as compared to the combination boceprevir with pr and to pr alone in the management of chronic hepatitis c in the netherlands. ispor europe conference nov 3-7 2012. pin61. nov 5 2012.
mcewan p, foos v, chraibi m, lloyd a, palmer jl, lamotte m, grant d. random number generators in monte carlo simulation. ispor europe conference nov 3-7 2012. prm50. nov 6 2012.
foos v, mcewan p, lloyd a, palmer jl, lamotte m, grant d. minimum run-time requirements to reduce monte carlo error in stochastic simulations. ispor europe conference nov 3-7 2012. prm52. nov 6 2012.
foos v, palmer jl, grant d, lloyd a, lamotte m, mcewan p. long-term validation of the ims core diabetes model in type 1 and type 2 diabetes. ispor europe conference nov 3-7 2012. prm58. nov 6 2012.
mcewan p, foos v, lloyd a, palmer jl, lamotte m, grant d. correlating cost-effectiveness output with patient level data input via the ims core diabetes model (cdm). ispor europe conference nov 3-7 2012. prm54. nov 6 2012.
foos v, mcewan p, lloyd a, palmer jl, lamotte m, grant d. assessing the relationship between the effect of glycemic control and avoided symptomatic hypoglycemia on quality of life in the management of type 2 diabetes. ispor europe conference nov 3-7 2012. db1. nov 5 2012.
duran a, spaepen e, lamotte m, gutiérrez l. comparación de agentes estimulantes de la eritropoyesis (aee) en el tratamiento de la anemia inducida por quimioterapia en españa. published in congress book of the liv reunión nacional de la sehh y xxviii congreso nacional de la seth, salamanca 18 - 20 october 2012. nº definitivo: pb- 216

2011

duran a, spaepen e, lamotte m, walter e, kutikova l, pujol b, annemans l. cost analysis of anemia treatment with erythropoiesis-stimulating agents in cancer patients receiving chemotherapy. 16th congress of the eahp, vienna march 2011. abstract number ohp016.
k. moeremans, s. sharma, m. lamotte, m. gallagher. health economic consequences of systemic safety differences between ranibizumab and unlicensed bevacizumab. poster presented at the 2nd world congress on controversies in ophthalmology (cophy). catalonia palace of congresses, barcelona, spain, march 3-6, 2011. poster 41.
sharma s, moeremans k, lamotte m, gallagher m. potential safety differences between unlicensed bevacizumab (avastin®) and ranibizumab (lucentis®) in age-related macular degeneration (amd) - a health economic perspective. 11 th euretina congress, may 29-29, 2011. london, uk
duran a, spaepen e, lamotte m, walter e, lucioni c, pinheiro b, brosa m, kutikova l, pujol b, annemans l. cost analysis of anemia treatment with erythropoieses-stimulating agents (esas) in patients with cancer receiving chemotherapy: a multi-country approach. ispor 16th annual international meeting; may 21-25, 2011; baltimore, md, usa
chevalier p, lamotte m, malfait m, marciniak a. the incidence and outcome of febrile neutropenia in different chemotherapy regimens for cancer patients in belgium. ecco congress on september 24, 2011, poster nr. 3.533.
f. nevens, i. colle, p. michielsen, g. robaeys, c. moreno, k. caekelbergh, m. lamotte, v. wyffels. resource use and cost of hepatitis c related care in belgium. belgian week of gastroenterology thursday feb 9 2012 a19 125
caekelbergh k, lamotte m, nevens, colle, michielsen, robaeys, moreno c, wyffels v. resource use and cost of hepatitis c related care in belgium. ispor europe madrid nov 7-9 2011 pgi14.
chevalier p, lamotte m, malfait m, marciniak a. the incidence and outcome of febrile neutropenia in different chemotherapy regimens for cancer patients in belgium. europe madrid nov 7-9 2011 pcn7
gerlier l, schlaen r, lorenz k, lamotte m, verboven y, pfeiffer n. glaucoma management cost as a function of disease stage and treatment changes. europe madrid nov 7- 9 2011. pss19
gerlier l, shlaen r, wolfram c, lamotte m, verboven y. visual field evolution in glaucoma patients presenting with different disease stages: results from an observational study. europe madrid nov 7-9 2011. pss5
gerlier l, lamotte m, lorenz k, berdeaux g, verboven y, pfeiffer n. economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad® instead of benzalkonium chloride in germany. europe madrid nov 7-9 2011. pss10
gerlier l, lamotte m, berdeaux g, verboven y, pfeiffer. longer term patient benefits of polyquad® preservative instead of benzalkonium chloride in prostaglandin eye drops: a microsimulation model in ocular hypertension and open-angle glaucoma. europe madrid nov 7-9 2011. pss4
duran a, spaepen e, lamotte m, brosa m, gutierrez l, restovic g, annemans l. cost analysis: treatment of chemotherapy-induced anaemia with erythropoiesis-stimulating agents (esas) in spain. europe madrid nov 7-9 2011. pcn33
duran a, spaepen e, lamotte m, lucioni c, kutikova l, pujol b, gozzo m, annemans l. cost analysis of anemia treatment with erythropoiesis-stimulating agents (esas) in cancer patients receiving chemotherapy in italy. europe madrid nov 7-9 2011. pcn34
leeuwenkamp o, chevalier p, lamotte m. evaluation of the clinical and economic burden of chronic constipation in belgium. europe madrid nov 7-9 2011. pgi13

2010

dratwa m, bogaert a, caekelbergh k, lamotte m, laplante s. the cost of dialysis in belgium. poster presentation at the xlvii era-edta congress, in munich, germany, (june 25-28, 2010).
akoua-koffi c, lamotte m. does acute gastro enteritis in infants and children impact the quality of life of parents? a questionnaire survey in the cote d’ivoire (ivory coast)" poster presentation at the 9th international rotavirus symposium (johannesburg-south africa_2-3 august 2010).
curran d, lamotte m, van kriekinge g. quality of life impact in parents caring for severe gastroenteritis in children in 7 countries worldwide. ispor asia september 2010, pukhet, thailand.
dratwa m, bogaert am, bouman k, caekelbergh k, lamotte m, s laplante s. les couts de la dialyse en belgique. poster presentation at 12ème réunion commune des sociétés de néphrologie et de dialyse - bruxelles september 30 2010.
gerlier l, lamotte m, verboven y. glaucoma disease progression states: establishing a direct, quantitative link between visual field defects and utility loss. ispor europe prague november 2010.
caekelbergh k, lamotte m, dratwa m, bogaert am, bouman k, laplante s. resource use and costs of patients undergoing dialysis in belgium. ispor europe prague november 2010.
chevalier p, lamotte m, leenaerts p. a health economic evaluation of the switch of erythropoiesis-stimulating agents (esas) in patients with renal failure undergoing haemodialysis. ispor europe prague november 2010.
chevalier p, lamotte m. an epidemiological evaluation of the incidence of deep venous thrombosis and pulmonary embolism in patients with hip or knee replacement surgery and of its impact on the average length of stay. ispor europe prague november 2010.
chevalier p, lamotte m. an epidemiological evaluation of the impact of percutaneous coronary interventions on the length of stay and mortality of patients hospitalized with acute coronary syndromes. ispor europe prague november 2010.
laplante s, walker dr, caekelbergh k, lamotte m, dratwa m, bogaert am, bouman k. patient co-morbidities affect the cost of dialysis patients in belgium. ispor europe prague november 2010.
duran a, spaepen e, lamotte m, walter e, kutikova l, pujol b, annemans l. real-life cost analysis of anemia treatment with erythropoiesis stimulating agents in cancer patients receiving chemotherapy. ash conference 2010 december 6. abstract 3811.

2009

moeremans k, lamotte m, witrup-jensen ku, pignone m. the health economic value of aspirin in the primary prevention of cardiovascular disease in diabetic patients. oral presentation at american diabetes association congress new orleans 2009, june 6..
lamotte m, maugars y, de vos c, le lay k, taïeb c. health economic comparison of outpatient management of fibromyalgia before and after diagnosis in five european countries. poster at eular congress 2009, copenhagen 10-13 of june.
vinereanu d, cinteză m, ţele p, gerlier l, lamotte m. a health-economic evaluation of highly concentrated and purified omega-3 polyunsaturated fatty acids (n-3 pufas) in the secondary prevention after myocardial infarction (mi) in romania “the 48th romanian national cardiology congress” 19-22 september 2009, sinaia, romania.
caekelbergh k, lamotte m, van megen y. management of opioid induced constipation (oic) in pain patients: a cost of illness study in belgium and the netherlands. ispor europe paris october 2009. poster pgi 7.
m. lamotte, y. maugars, k. le lay, c. taïeb. health economic comparison of outpatient management of fibromyalgia before and after diagnosis in five european countries. ispor europe paris october 2009. poster pms 29.
m. lamotte, y. maugars, k. le lay, c. taïeb. costs avoided by diagnosing fibromyalgia. ispor europe paris october 2009. poster pms 28.
van den steen d, petit c, lamotte m. the cost-effectiveness of titration to goal with brand rosuvastatin compared to generic simvastatin in patients with elevated low-density lipoprotein cholesterol: primary and secondary prevention in the belgian health care setting. ispor europe paris october 2009. poster pcv 94.
gerlier l, lamotte m, wille m, dubois d. cost-utility of autologous chondrocytes implantation using chondrocelect ® in symptomatic knee cartilage damage in belgium. ispor europe paris october 2009. poster pms 56.
gerlier l, lamotte m, van megen y. treatment of moderate to severe pain with oxycodone/naloxone to reduce opioid-induced constipation: a cost-utility analysis in belgium and the netherlands. ispor europe paris october 2009. poster pgi 15.
ramos m., oliveira m.c., barros p.p. estimating mental health production functions: what does explain the mental health status of the portuguese population. 2009. 11 th portuguese health economics conference. poster: 680455 (awarded with best poster)

2008

lecomte p, lamotte m, esposito g, annemans l, kotchie r w, munk vc, vincze g. belgian budget impact analyses of aliskiren (tekturna/rasilez) in hypertension. poster presented at the ispor 13th annual international meeting – 3-7 may 2008 – presentation code: pcv26.
van den steen d, van bellinghen la, liwing j, van vlaenderen i, lamotte m, lothgren m, annemans l. cost-effectiveness of fentanyl its (ionsystm) in post-operative pain management: a finnish hospital perspective analysis ispor 11th annual european congress 2008, athens, greece.
van bellinghen la, lamotte m, malfait m a health economic evaluation of the use of erythropoiesis-stimulating agents (esa) in patients with renal failure treated with heamodialysis ispor 11th annual european congress 2008, athens, greece.
gerlier l, de vos c, lamotte m, malfait m, poitrinal p. epidemiology of idiopathic thrombocytopenic purpura in belgium assessed using hospital records. ispor 11th annual european congress 2008, athens, greece.
gerlier l, lamotte m, van lommel n, wille m, vanlauwe jj. relief of pain and symptoms in knee cartilage defect is associated with higher sf-36 utility scores: data from a prospective randomized trial of chondrocelect® ispor 11th annual european congress 2008, athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. costs avoided by diagnosing fibromyalgia in spanish patients. ispor 11th annual european congress 2008, athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. health economic evaluation of outpatient management of fibromyalgia in spain. ispor 11th annual european congress 2008, athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. costs avoided by diagnosing fibromyalgia in french patients ispor 11th annual european congress, athens 2008, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. health economic evaluation of outpatient management of fibromyalgia in france ispor 11th annual european congress 2008, athens, greece.
caekelbergh k, lamotte m, muchada jp. management of herpes zoster (hz) and post-herpetic neuralgia (phn) in belgium: a cost of illness study. ispor 11th annual european congress 2008, athens, greece.
strens d, lamotte m. medical resource consumption related to the treatment of irinotecan refractory advanced colorectal cancer patients. ispor 11th annual european congress 2008, athens, greece.
maugars y, lamotte m, van vlaenderen i, le lay k, taieb c. paramedical or alternative treatments and associated costs for the management of fibromyalgia in france. ispor 11th annual european congress 2008, athens, greece.
maugars y, lamotte m, van vlaenderen i, le lay k, taieb c. outpatient medical management of fibromyalgia in france compared to the united kingdom. ispor 11th annual european congress 2008, athens, greece.
van bellinghen la, van den steen d, liwing j, lamotte m, lothgren m, annemans l. cost- effectiveness of fentanyl its (ionsystm) in post-operative pain management: a swedish hospital perspective analysis. sfai 2008 vetenskap congress, uppsala, sweden.

2007

dendale p, hansen d, berger j, vaes j, reenaers v, lamotte m. long term effects and cost effectiveness of multidisciplinary cardiac rehabilitation after percutaneous coronary intervention. poster at annual congress of belgian society of cardiology february 2007.
esposito g, lamotte m, annemans l, bracco a. a cost-consequence analysis of darbepoetin alfa administered every 3 weeks (q3w_da) compared to weekly epoetin alfa (qw_ea) or epoetin beta (qw_eb) in patients with chemotherapy- induced anemia (cia): the italian case. ispor 10 th annual european congress. contributed poster presentations session ii - monday, 22 october. value in health 2007; volume 10, issue 6. a324 - pcn8
van bellinghen la, esposito g, lamotte m, bracco a, goertz a, annemans l. a cost- consequence analysis of darbepoetin alfa administered every 3 weeks (q3w_da) compared to weekly epoetin alfa (qw_ea) or epoetin beta (qw_eb) in patients with chemotherapy-induced anemia (cia): the german case. ispor 10 th annual european congress. contributed poster presentations session ii - monday, 22 october. value in health 2007; volume 10, issue 6. a328 - pcn19
demarteau n, braeckman j, michielsen d, sweet a, zyczynski t, lamotte m. a health economic evaluation of hexvix as adjunct to standard white light cystoscopy in the management of superficial bladder cancer. ispor 10 th annual european congress. contributed poster presentations session ii - monday, 22 october. value in health 2007; volume 10, issue 6. a328 - pcn 21

2006

lamotte m, annemans l, evers t, kubin m, hu s. a health economic evaluation of aspirin in the primary prevention of cardiovascular disease. 2 nd asia-pacific congress of the international society of pharmacoeconomics and outcome research – shanghai, china, march 5-7 2006. pcv4.
mark lamotte, lieven annemans, marie-christine herregods, jean-claude daubresse, georges michel, guy vandenhoven, eugène vissers. the cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery belux-study. poster at europrevent congress athens may 11-13 2006, poster id: 52.
lamotte m, annemans l, schockaert b the impact of dose increase on the cost- effectiveness of statins. ispor 11th annual international meeting may 20-24, 2006 marriott philadelphia, philadelphia, pa. pcv27
lamotte m, annemans l, evers t, kubin m, hu s. a health economic evaluation of aspirin in the primary prevention of cardiovascular disease. ispor 2nd asia- pacific conference to be held at the worldfield convention hotel, shanghai, china, 5-7 march 2006
lamotte m, annemans l, van loy r, koch w. a cost-effectiveness analysis of olmesartan in the treatment of arterial hypertension 9th european congress of the international society of pharmacoeconomics and outcome research – copenhaguen, denmark, october 28-31 2006. value in health 2006 pcv34
lamotte m, annemans l, siebert m a health economic evaluation of concomitant surgical ablation for atrial fibrillation 9th european congress of the international society of pharmacoeconomics and outcome research – copenhaguen, denmark, october 28-31 2006. value in health 2006 pcv36
lamotte m, annemans l, raskin a, hansen d, dendale p. a cost-effectiveness analysis of cardiac rehabilitation after percutaneous coronary interventions 9th european congress of the international society of pharmacoeconomics and outcome research – copenhaguen, denmark, october 28-31 2006. value in health 2006 pcv40
strens d, lamotte m, fassotte c, annemans l. burden of illness of abdominal obesity: a retrospective chart review. monday, 30 october 2006 08:00 - 19:30 at the ispor 9th annual european congress, 28-31 october 2006, radisson sas falconer hotel & conference center, copenhagen, denmark. value in health 2006.

2005

m lamotte, l annemans, k el ouagari, a gnanasakthy, zm khan: managing post-mi patients with an angiotensin ii receptor blocker: a health economic evaluation of real-life long-term consequences. esc congress, stockholm, 6 sept 2005: poster number 3630.
m lamotte, l annemans, a gnanasakthy, zm k. a health-economic evaluation of the real life long-term consequences of valsartan in the management of post mi patients. 10 th international congress of the international society of pharmacoeconomics and outcome research - waschington dc, us, may 14-18 2005. value in health 2005
ethgen o, lamotte m, annemans l. health economic evaluation of bivalirudin in the management of patients undergoing percutaneous coronary intervention in belgium. 8th european congress of the international society of pharmacoeconomics and outcome research – florence, italy, november 6-8 2005. value in health 2005.
lamotte m, annemans l, schockaert b. a cost-effectiveness analysis of candesartan in the treatment of chronic heart failure 8th european congress of the international society of pharmacoeconomics and outcome research – florence, italy, november 6-8 2005. value in health 2005 cv3
lamotte m, annemans l, evers t and kubin m. a cost-effectiveness analysis of low- dose aspirin in the primary prevention of cardiovascular disease in four european countries. 8th european congress of the international society of pharmacoeconomics and outcome research – florence, italy, november 6-8 2005. value in health 2005 pcv 33

2004

palmer aj, annemans l, roze s, lamotte m, rodby ra, ritz e. health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in germany. dtsch med wochenschr 2004; 129: 13-8.
lamotte m, cleemput i, annemans l. a health economic evaluation of 6-months alfuzosin treatment in the management of acute urinary retention. value in health 2004; 7: 800.
lamotte m, annemans l, evers t, kubin m. a health economic evaluation of aspirin in the primary prevention of cardiovascular disease. value in health 2004; 7: 637. best podium presentation award winner.
palmer aj, annemans l, roze s, lamotte m, rodby ra, bilous rw. an economic evaluation of the irbesartan in diabetic nephropathy trial (idnt) in a uk setting. j hum hypertens. 2004 apr 29

2003

palmer aj, annemans l, roze s, lamotte m, rodby ra, cordonnier dj. an economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost- effectiveness of irbesartan in diabetic nephropathy trial (idnt) in the belgian and french settings. nephrol dial transplant. 2003 oct;18(10):2059-2066.
palmer aj, annemans l, roze s, lamotte m, lapuerta p, gabriel s, chen r, carita p,villadary i, rodby r, de zeeuw d, parving hh. irbesartan is projected to be cost and life saving in the french setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. value in health 2003; 6: 615.
lamotte m, annemans l, de keyser p. a health economic evaluation of n-3 polyunsaturated fatty acids (pufa) in the secondary prevention after mi. value in health 2003; 6: 629.
lamotte m, caekelbergh k, annemans l, de keyser p. assessment of the cost of cardiovascular death. value in health 2003; 6: 658 (poster).
palmer aj, borsos k, roze s, annemans l, lamotte m, rodby r,valentine wj. irbesartan is cost-saving compared to amlodipine and standard blood pressure treatment in patients with type 2 diabetes, hypertension and nephropathy in hungary. value in health 2003; 6: 662 (poster).
magaz s, badia x, annemans l, lamotte m. cost-effectiveness analysis of coronary revascularisation techniques available for the treatment of ischaemic heart disease .value in health 2003; 6: 668 (poster).
lamotte m, massaer k,vranckx k, annemans l. a cost analysis of alfuzosin in the management of acute urinary retention. value in health 2003; 6: 703 (poster).

2002

lamotte m, annemans l, de jong p: drug eluting stents in coronary artery disease: assessment of outcomes and cost-effectiveness. eur heart j 2002; 23 (suppl): 137: 810 + oral presentation at esc 2002.
marchetti m, tarricone r, lamotte m, annemans l, de jong p: cost-effectiveness and budget impact of the sirolimus-eluting stent in the stent era. value in health 2002; 5: 457: hs1 + oral presentation at ispor 2002.
palmer aj, annemans l, roze s, lamotte m, guilhaume c, gabriel s, carita p, chen r, simon t, rodby r, cordonnier dj: the health-economic impilications of the irbesartan in diabetic nephropathy trial (idnt) in france and belgium. value in health 2002; 5: 546: pdb4 + poster at ispor 2002.

2001

annemans l, lamotte m, huybrechts m. issues and problems encountered in models on prevention of deep venous thrombosis (dvt) ispor 6th annual international meeting may 20-23, 2001. ww3
lamotte m, annemans l, peys f: gezondheidseconomische aspecten van interventies in de preventie en behandeling van diabetes in belgië. bige-briefing maart 2001; 1-8.
lamotte m, annemans l, peys f: ethische en economische aspecten van de diabetesvoet in belgië. bige-briefing september 2001; 6-8.
m. lamotte, l. annemans, a. lefever, m. nechelput, j. masure: orlistat in obese type 2 diabetic patients: assessment of long-term outcomes and cost-effectiveness. value in health 2001; 4 (6): 408 (cv5) + oral presentation at ispor 2001.

2000

l. annemans, m. lamotte, m. keech, k. wilson: health economic model to describe the current and expected burden of copd. value in health 2000; 3 (5); 328 (prs 4).

1996

m. lamotte, l. lasser, p. dendale, a. ae rts, m. noppen, p. melis, p. block: influence of sympathicolysis of d2-d3 on rate and blood pressure in patients with hyperhidrosis. oral poster presentation on annuel scientific meeting of the belgium society of cardiology; 31 jan. ‘97 + abstract in acta cardiologica. vol. 51, 6, 1996: 568-9.
a. aerts, p. dendale, m. lamotte, l. lasser, p. block: influence of tilt duration on diagnostic value in sublingual nitrate stimulated head up tilt testing. oral poster presentation on annuel scientific meeting of the belgium society of cardiology; 31 jan. ‘97 + abstract in acta cardiologica. vol. 51, 6, 1996: 586.

Our bibliography

full articles

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2010

2009

2008

2007

2006

2005

2004

2003

2002

2000

1997

1995

posters, abstracts and workshops

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1996